Inhaled vaporized cannabis does not appear to improve or worsen exercise performance and activity-related breathlessness in patients with advanced chronic obstructive pulmonary disease (COPD), according to a randomized controlled trial published online in Annals of the American Thoracic Society.
The study, "Effect of Vaporized Cannabis on Exertional Breathlessness and Exercise Endurance in Advanced COPD: A Randomized Controlled Trial," was led by Sara Abdallah, PhD candidate in exercise physiology with our Department of Kinesiology and Physical Education (KPE). Co-authors included KPE professor Dennis Jensen, Director of the McGill Research Centre for Physical Activity and Health (PATH); Ben Smith (PATH), Jean Bourbeau (PATH), and Michelle Moore (KPE student).
"Senior study author Dennis Jensen, PhD, associate professor of kinesiology and physical education and a scientist in the Translational Research in Respiratory Diseases Program at McGill University, said that trial results may not be generalizable because the number of participants was small and represented a relatively homogenous group of patients with stable, but advanced, COPD," wrote the report published by the American Thoracic Society in part. Numerous media outlets picked up the story including:
- Science Daily, "Cannabis does not improve breathlessness during exercise in patients with advanced COPD"
- UPI, "Medicinal marijuana not effective against COPD symptoms in small study"
- Health Day, "Vaping Medical Pot May Not Ease COPD Symptoms: Study"
To read the study, published July 27 in Annals of the American Thoracic Society, please click here.